EGFR and chronic obstructive pulmonary disease: The data is novel because no previous data implicates EGFR activation in skeletal muscle fiber-type specification nor identifies a signaling mechanism related to ST fiber loss in COPD that is targetable by clinically available pharmacotherapies.